Quantcast

Latest Bisphosphonate Stories

80bade0876dca47b498c6ccbe4a1d1d51
2010-10-17 08:55:00

Forteo, a drug produced by Eli Lilly and Co. and used for osteoporosis, has been found to be able to re-grow bone in jaws damaged by severe bone-destroying conditions called osteonecrosis and periodontitis, doctors reported on Saturday.The research suggests that the drug may drive growth in a damaged jaw, according to researchers.Forteo, known as teriparatide generically, cuts the risk of bone fractures by half in patients with thinning bones by stimulating the growth of new bone. But the...

2010-10-14 16:01:00

THOUSAND OAKS, Calif., Oct. 14 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several Prolia(TM) (denosumab) studies, as well as analyses of the growing global burden of osteoporosis, will be presented at the 2010 American Society for Bone and Mineral Research (ASBMR) annual meeting in Toronto, Ontario from Oct. 15-19, 2010. "The continued need to reduce fractures caused by postmenopausal osteoporosis is reinforced by data that will be presented at this year's...

2010-10-13 12:29:00

Labeling change adds warning about possible risks of long-term use of osteoporosis drugs SILVER SPRING, Md., Oct. 13 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk. (Logo:...

2010-09-30 07:00:00

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that three quarters of surveyed endocrinologists and rheumatologists who are aware of Amgen/GlaxoSmithKline's Prolia anticipate prescribing the drug. However, according to Treatment Algorithms in Osteoporosis, while awareness of Prolia is good among specialists (94 percent of surveyed endocrinologists and 85 percent of...

2010-09-24 08:15:00

PRAGUE, Sept. 24 /PRNewswire/ -- Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages. Michael Whyte, MD, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research...

2010-09-03 17:48:50

Research: Oral bisphosphonates and risk of cancer of the esophagus, stomach and colorectum: Case-control analysis within a UK primary care cohort People who take oral bisphosphonates for bone disease over five years may be doubling their risk of developing oesophageal cancer (cancer of the gullet), according to a new study published on bmj.com today. Oral bisphosphonates are a type of drug used to treat osteoporosis and other bone diseases and are the most commonly recommended treatment for...

2010-08-10 23:26:30

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA. Bisphosphonates are mainly used to prevent or treat osteoporosis, especially in postmenopausal women....

2010-06-05 14:00:00

CHICAGO, June 5 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties. The findings were announced today at the 2010 American Society of Clinical Oncology...

2010-06-05 07:27:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of Zometa® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy(1). The 5.5...

2010-05-26 11:25:00

CHICAGO, May 26 /PRNewswire-USNewswire/ -- People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association (JADA). Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related